Vesicular storage and subsequent release of neurotransmitters are the key processes of chemical signal transmission. In this process, vesicular neurotransmitter transporters are responsible for loading the signaling molecules.
Chemical transmission plays a central role in intercellular communications (18, 84) . In neurons, neurotransmitters are accumulated in synaptic vesicles and released upon Ca 2ϩ -dependent exocytosis. The released neurotransmitters bind to specific receptors on the plasma membrane of target cells and thereby transmit a signal. Vesicular neurotransmitter transporters are responsible for the accumulation of neurotransmitters in synaptic vesicles, and, hence, they are an essential component of chemical transmission (FIGURE 1).
In synaptic vesicles, vacuolar-type H ϩ -ATPase of synaptic vesicles are 1.5 and 80 mV, respectively, and provide sufficient energy for the vesicular storage of neurotransmitters (53, 83, 84, 108) . The energy coupling of V-ATPase and a vesicular neurotransmitter transporter is a general mechanism of neurotransmitter transport into vesicles (18, 84) . This mechanism is found in various secretory vesicles in neuronal and nonneuronal systems such as monoamine accumulation in chromaffin granules of chromaffin cells. Here, we discuss the functional mechanism and regulation of vesicular neurotransmitter transporters.
Classification of Vesicular Neurotransmitter Transporters
Vesicular neurotransmitter transporters are classified into three families based on amino acid sequence, substrate specificity, inhibitors, and energetics. These are SLC17 (solute carrier family 17), SLC18, and SLC32 and comprise proteins that are responsible for the accumulation of anionic, cationic, and neutral transmitters, respectively ( Table 1) . The first group, SLC17 anion transporter family, mediates the uptake of glutamate, aspartate, and nucleotides. The SLC17 family includes three vesicular glutamate transporters (VGLUT1-3), the vesicular excitatory amino acid transporter (VEAT), and the vesicular nucleotide transporter (VNUT). The second group, SLC18 family transporters, are involved in the accumulation of cationic neurotransmitters. This family includes vesicular monoamine transporters (VMAT1 and VMAT2) and the vesicular acetylcholine transporter (VAChT) (21). The third group, SLC32, consists of a single member, vesicular GABA transporter (VGAT) (31). VGAT transports GABA and glycine, which are inhibitory neurotransmitters. Therefore, it is also known as vesicular inhibitory amino acid transporter (VIAAT).
The SLC18 Vesicular Monoamine Transporter Family
The cDNA of rat VMAT1 was identified and cloned by screening CHO cells resistant to N-methyl-4-phenylpyridinium (MPP ϩ ) after plasmid rescue (63) . The isolated cDNA encodes a protein with 12 putative transmembrane domains that belongs to a major facilitator super family (MFS) and does not resemble plasma membrane type monoamine transporters. Membrane vesicles isolated from VMAT1-overexpressing CHO cells showed ATP-dependent dopamine uptake that is sensitive to CCCP and reserpine. Rat VMAT2 was isolated by expression cloning and homology (22, 63) . Isolated human VMAT1 and VMAT2 cDNAs encoded two proteins that were 514 -525 amino acids long (24). The amino acid sequence identity of the two isoforms is 60%.
Immunohistochemical analyses revealed that VMAT2 and VMAT1 are mainly distributed in the central nervous system or peripheral systems, respectively (23, 24, 85) . Monoamine uptake by VMAT was extensively studied using isolated chromaffin granules since their monoamine concentration is ϳ1 M (50 in Caenorhabditis elegans (6). Later, the rodent homolog was isolated by vesamicol-sensitive acetylcholine accumulation (25). Shortly after, the human VAChT cDNA was isolated by homology cloning based on unc-17 and rodent VAChT cDNA sequences (23, 87). Similar to the VMATs, human VAChT cDNA encodes a 532-amino acid-long protein with 12 putative transmembrane domains. It shows only 39% sequence identity with human VMAT1, which suggests a distinct function for VAChT. The kinetic features of VAChT have been characterized using Torpedo electric organ synaptic vesicles (9, 10, 81). Like the VMATs, VAChT is a typical H ϩ antiporter with a stoichiometry of 2H ϩ /acetylcholine molecule taken up (81) . However, in contrast to VMATs, the K m for acetylcholine is ϳ0.4 mM, which is significantly higher than that of VMATs (9). VAChT is specifically inhibited by vesamicol with a dissociation constant of ϳ34 nM (9, 10).
The SLC32 Vesicular GABA Transporter Family
VGAT is the sole member of the SLC32 family, and no isoform is known (31). SLC32 is distantly related to the SLC36 lysosomal amino acid transporter (LYAAT) and SLC38 sodium-coupled neutral amino acid transporter families. The SLC32 family is not homologous to the SLC17 or SLC18 families. The first VGAT cDNA was isolated during studies on the failure of GABAergic signal transmission in nematodes. The unc-47 gene of Caenorhabditis elegans was identified through abnormally high GABA accumulation in GABAergic neurons (66) . After the unc-47 gene was isolated, rodent counterparts were cloned by in situ hybridization and PCR (67, 91) . The isolated cDNA encoded a 495-amino acid-long protein for mouse and a 525-amino acid-long protein for rat. The hydropathy analysis predicted 10 GABA Glycine ⌬ 2Cl Ϫ /GABA cotransport Brain, islets of Langerhans, testis transmembrane domains for each protein. When rat cDNA was introduced to PC12 cells, the membrane fractions showed GABA transport activity (67) . In situ hybridization and immunohistochemistry of VGAT revealed that the transporter is expressed in the GABAergic and glycinergic neurons of neocortex, hippocampus, cerebellum, striatum, septal nuclei, and reticular nucleus of the thalamus (19, 67) . The presence of VGAT in the glycinergic neurons and the significant enhancement of glycine uptake after introduction of VGAT cDNA in COS7 cells indicate that VGAT also transports glycine (19, 91) . Inactivation of the VGAT gene causes embryonic death and diminishes GABAergic and glycinergic signal transmission (109) . Glycine transport by VGAT was also confirmed by a later study using purified VGAT (55). Since VGAT transports GABA and glycine, expression of the GABA synthetic enzyme, glutamate decarboxylase (GAD), plays a key role in GABAergic neuronal functions (49). In a related matter, one of the isoforms, GAD65, is reported to form a complex with VGAT on the synaptic vesicles (49). VGAT transports GABA with a K m of ϳ5 mM and inhibited by CCCP (30). Similar results were obtained with membrane vesicles from PC12 cells after introduction of VGAT cDNA (67) . Cytoplasmic GABA concentration has not been well characterized but is estimated to be in the millimolar range (26). The high K m value may reflect the abundance of GABA in the cytoplasm. GABA transport by these vesicles is strongly inhibited by valinomycin but is less sensitive to nigericin, indicating that membrane potential rather than a H ϩ gradient is the driving force (41 
The SLC17 Anion Transporter Family
Glutamate is a major excitatory neurotransmitter and is stored in synaptic vesicles by SLC17 family transporters (84) . This family includes nine transporters. Five of these are involved in vesicular transport of glutamate, aspartate, and ATP. The remaining four transporters are known as the Na ϩ -dependent inorganic phosphate transporter (NPT) family and play essential roles in anionic drug export in the kidney, liver, and intestines (46, 102). Vesicular accumulation of glutamate was studied using isolated synaptic vesicles (79, 80) . These studies showed that ATP-dependent glutamate transport is driven by the electrochemical gradient of H ϩ . This activity is sensitive to CCCP and bafilomycin A1 and thus suggests a V-ATPasecoupled glutamate transport system. However, the protein responsible for glutamate transport was not known until identification of the SLC17 family.
The first member of SLC17 family (NPT1) was identified as a renal Na ϩ -dependent inorganic phosphate transporter through expression cloning (107) . Although it was expected to be a plasma membrane phosphate transporter, subsequent biochemical analyses revealed that the physiological function of NPT1 was an anionic drug exporter (46). After identification of NPT1, another cDNA, designated BNPI (brain-specific Na ϩ -dependent inorganic phosphate cotransporter I), was isolated by subtractive cloning from NMDA-treated cerebellar granule cells (82) . The BNPI cDNA encoded a 502-amino acid residue-long membrane protein whose sequence was 32% identical to that of NPT1. In contrast to NPT1, BNPI is specifically expressed in synaptic vesicles of neurons, suggesting a specific role in signal transmission (13) . Another group identified the eat-4 gene, which is responsible for defective glutamatergic signaling in Caenorhabditis elegans (61) . The predicted amino acid sequence of the eat-4 gene product shows 48% identity with that of BNPI. Later, Bellochio and coworkers found glutamate transport activity in BNPI by using membrane vesicles isolated from cells heterologously expressing the protein (14, 98) . The kinetic profile and inhibitor sensitivity of glutamate transport in isolated membrane vesicles from BNPIexpressing cells share the same properties as those of synaptic vesicles. Based on these studies, the authors concluded that BNPI is the vesicular glutamate transporter (VGLUT1). The cDNA of the second isoform of VGLUT was isolated as differentiation-associated Na ϩ -dependent phosphate transporter (DNPI) from rat pancreatic AR42J cells after differentiation into neuron-like cells by activin A treatment (5). As with BNPI, DNPI localized to synaptic vesicles and membrane vesicles prepared from DNPI cDNA transfected cells exhibited glutamate transport activity (11, 39, 42, 99, 103) . The third isoform of VGLUT was identified by cDNA cloning based on sequence similarity and was confirmed to be a novel vesicular glutamate transporter by localization to synaptic vesicles. Glutamate transport activity was demonstrated using an expression system (27, 32, 93).
The isolated VGLUT cDNAs encoded proteins with 12 putative transmembrane regions and are predicted to be 560 -600 amino acid residues long. The amino acid sequence shows that VGLUTs are typical MFS type transporters and have significant sequence similarity to SLC18 but not to SLC32 family transporter. In contrast to other SLC17 proteins, VGLUTs have a longer cytoplasmic carboxyl terminal region. This region contains signals for vesicular localization and internalization from plasma membrane (106) .
Interestingly, the three isoforms of VGLUTs have different tissue distributions. Although the biochemical properties of three isoforms are very similar, the different expression patterns suggest functional differences between the isoforms. In the central nervous system, VGLUT1 is mainly expressed in the cerebral cortex, hippocampus, and cerebellar cortex, whereas VGLUT2 is mainly expressed in the thalamus, brain stem, and deep cerebellar nuclei (29, 42, 99, 103) . On the other hand, VGLUT3 is expressed in cholinergic and serotoninergic neurons (27, 32, 93). The distribution of VGLUT3 in non-glutamatergic cells suggests the presence of a novel mode of glutamate signaling. In addition to the central nervous system, VGLUTs are also found in various peripheral tissues such as the pineal gland, the islet of Langerhans, osteoclasts, and testes, thus showing the diverse function of glutamate (37, 38, 44, 73, 74, 78, 86) . In bone, VGLUT1 is expressed in the osteoclasts and is involved in the autoregulation of bone degradation by these cells (74) . In the islet of Langerhans, VGLUT1 and VGLUT2 are found in glucagon-containing secretory granules of ␣-cells and are co-released with glucagon and modulate GABA secretion from ␤-cells (38).
The importance of VGLUTs in glutamatergic signaling has been confirmed by gene knockout studies (28, 72, 74, 95, 96, 101, 110) . Targeted deletion of the VGLUT1 gene inhibited glutamatergic signal transmission with decreased glutamate uptake and quantal size, which shows the importance of VGLUT1 on glutamatergic signaling (28, 110). Consistent with the predominant expression of VGLUT2 in the embryonic and early postnatal development stages, VGLUT2 gene knockout is lethal (71, 72) . In contrast to VGLUT1 and VGLUT2, gene disruption of VGLUT3 revealed involvement of this gene product in auditory function and mechanical hypersensitivity and, hence, a more specific role of this isoform (95, 96) .
Biochemical Properties of VGLUT
In the beginning, VGLUTs were characterized using isolated synaptic vesicles. ATP-dependent glutamate transport is sensitive to CCCP and valinomycin and thus showed that an electrochemical gradient of H ϩ was the driving force (79, 80) . Although glutamate transport is slightly decreased by nigericin, strong inhibition by the membrane potential dissipater valinomycin indicates that the driving force is an insidepositive membrane potential rather than a H ϩ gradient (11, 14, 17, 29, 32, 42, 54, 56, 65, 77, 80, 103) . Since glutamate is anionic under physiological conditions, an inside-positive membrane potential provides sufficient energy for glutamate accumulation. The calculated magnitude of the concentration difference of glutamate established by membrane potential is ϳ22-fold (84). This value is close to the measured concentration gradient of ϳ10 in synaptic vesicles, indicating that membrane potential is the sole driving force of VGLUT (15 Although these compounds are used as VGLUT inhibitors, they also inhibit other SLC17 family transporters (69, 92) . DIDS, which is well known as an inhibitor of anion transporters, also inhibits VGLUT and other SLC17 family transporters such as NPT and VNUT (36, 46, 54, 77, 88, 92, 100) . In contrast to azo dyes, DIDS competes with Cl Ϫ , suggesting that the binding site of DIDS is close to that of Cl Ϫ (36, 54, 77).
The similar inhibitor sensitivities of SLC17 family transporters suggest a conserved structure of the substrate and Cl Ϫ binding sites.
Clean Biochemical Approach
Vesicular neurotransmitter transporters are attractive subjects for neuroscience since they affect presynaptic regulation of signal transmission through vesicular loading of neurotransmitters and quantum size. Identification of transporter genes and development of new techniques such as gene targeting, RNAi, real-time PCR, and immunohistochemistry enabled us to do detailed analysis on the physiological functions of these transporters. However, the molecular mechanisms of vesicular neurotransmitter transporters are not well understood because of the lack of innovative techniques on membrane biochemistry. Currently, heterologous expression in Xenopus oocytes and various mammalian cells are widely used for kinetic analysis of transporters. However, the co-existence of other transporters and ion channels in the membranes makes it difficult to perform precise kinetic analyses. In addition, it is hard to control the concentration of transporters in the membranes as well as in the intravesicular condition that is important to identify substrates and the driving force. Our solution to this situation is the "clean biochemical" approach with proteoliposomes containing purified recombinant proteins (FIGURE 2A) (84) . This approach was originated by Kasahara and Hinkle in their work on the purification and reconstitution of the glucose transporter, for which they purified band 4 -5 from human erythrocyte membranes and reconstituted glucose transport activity upon incorporation of band 4 -5 protein into egg yolk phosphatidylcholine liposomes (57). Since then, many transporters have been solubilized from their original membranes, purified to homogeneity, and reconstituted into proteoliposomes. Due to the success of genome projects, cDNAs encoding transporters from various species can be easily obtained. His-tagged transporters from any species can be overexpressed in insect cells or bacteria and purified through Ni-NTA column chromatography (56, 62). We wondered whether the purified, tagged recombinant transporters were active upon reconstitution. If this were the case, we could treat any transporter in this manner and measure and study their transport activity under the same assay conditions. For the past decade, we have expressed, purified, and reconstituted Ͼ100 different transporters from plants and mammals and found that the thus reconstituted purified transporters are fully active and have concluded that the procedure is a 
Mechanistic Studies on VGLUT
We have successfully applied "clean biochemistry" to the characterization of VGLUT2 (56). Purified VGLUT2 was incorporated into liposomes with F-type H ϩ pump purified from bacteria (76 VGLUT is a peculiar protein that contains two different transport machineries in a molecule. Further analysis of SLC17 family transporters revealed that such multi-transport machinery is a common feature of this family (46, 69, 102).
FIGURE 2. The "clean biochemical" approach
A: neurotransmitter transport by purified transporter. Vesicular neurotransmitter transporters are overexpressed in either insect cells or bacteria as His-tagged proteins and purified through Ni-NTA column chromatography after solubilization of the membrane fraction with detergent. Purified transporters are reconstituted in liposomes. By controlling the concentration of components of the intravesicular solution and reaction mixture, an artificial H ϩ gradient or membrane potential is generated. Valinomycin-induced K ϩ entry generates an inside-positive membrane potential and drives glutamate transport by VGLUT. B: membrane potential-driven ATP transport by VNUT. V-ATPase interferes with nucleotide transport measurements. In the purified and reconstituted system, an artificial membrane potential imposed by valinomycin induces nucleotide transport without being affected by V-ATPase. 
Identification of Vesicular Nucleotide Transporter and Vesicular Excitatory Amino Acid Transporter
Intensive efforts during the past two decades have led to the identification of most of the major vesicular neurotransmitter transporters. However, a significant number of vesicular neurotransmitter transporters still have not been identified. For instance, D-serine, nucleotides, aspartate, polyamines, ascorbate, and divalent cations are stored in vesicles, but the molecular mechanism of and the proteins responsible for their accumulation are not known (50). The functional importance of these molecules is also not clear because of the lack of information on their vesicular accumulation and release.
ATP is well known as the "energy currency" from early biochemistry; however, it also functions as a signaling molecule (1, 16) . In purinergic signaling, ATP and its hydrolysis products, ADP, AMP, and adenosine, are used as transmitters. The discovery of purinoceptors proved the presence of a purinergic system (1, 16) . Vesicular accumulation of nucleotides is well documented in various secretory vesicles including chromaffin granules, synaptic vesicles of torpedo electric organs, brain, and dense granules of platelets (43, 50, 83). However, the mechanism of nucleotide accumulation in these vesicles is not understood. Biochemical studies on the nucleotide transport in vesicles showed ATP-dependent nucleotide transport (2, 12, 33, 43, 64, 112) . These studies revealed the presence of a KCl-dependent, DIDSsensitive nucleotide transporter. However, these transport analyses were hampered by ATP hydrolysis and binding by V-ATPase. Efforts to isolate vesicular nucleotide transporter have not been successful because of the dilemma in measuring vesicular ATP transport (60, 90). When secretory vesicles are used to measure ATP transport, some ATP must be first hydrolyzed by the vacuolar ATPase to supply the driving force for the uptake. This makes the quantitative measurement of ATP transport difficult. On the other hand, without ATP hydrolysis, the vacuolar ATPase is not activated, and, consequently, no active transport of ATP occurs. Thus the molecule responsible for vesicular nucleotide transport was not identified until recently (43).
The "clean biochemistry" approach can bypass the V-ATPase problem and has been successfully used to identify the vesicular nucleotide transporter VNUT (43, 90, 92) . Based on the biochemical properties of nucleotide transport, we expected that a previously unidentified vesicular nucleotide transporter would be a novel member of the SLC17 family. Gene mining of the human genome led to the identification of a new SLC17 transporter gene that was tentatively named SLC17A9 (92) . The SLC17A9 protein is found in chromaffin granules, which are known to store large quantities of nucleotides. To exclude the complicating effects of a H ϩ -pumping ATPase, purified SLC17A9 protein was reconstituted as the sole protein component in liposomes. An inside-positive membrane potential was imposed by potassium diffusion by the addition of valinomycin (FIGURE 2B). As expected, the proteoliposomes showed strong ATP transport activity. Kinetic analysis showed that ATP transport was driven by membrane potential, required low concentrations of Cl Ϫ , and was inhibited by DIDS and Evans blue (92) . These properties are common to the SLC17 family. The ATP transport can be described by simple Michaelis-Menten kinetics with a K m value of 0.8 mM. In addition to ATP, the SLC17A9 protein transports ADP and GTP, but AMP is a poor substrate. Interestingly, atractyloside, an inhibitor of the mitochondrial ATP/ADP carrier, also inhibited ATP transport in the presence of Mg 2ϩ . The SLC17A9 protein was localized to secretory vesicles and suppression of SLC17A9 gene by RNAi-inhibited ATP release. These results clearly show that the SLC17A9 protein is the vesicular nucleotide transporter (VNUT). Another remarkable feature of VNUT is its ability to transport divalent cations (70) . Kinetic analysis revealed that VNUT transports both free and Mg ion complexed forms of nucleotides. This is quite interesting because ATP-storing vesicles also contain large quantities of divalent metal ions (50, 83). The experimental observations indicate that VNUT also contributes to Mg 2ϩ or Ca 2ϩ storage in these vesicles. The successful identification of VNUT by using the "clean biochemical" approach demonstrated the method's value for the identification of novel transporters.
So far, various mechanisms of nucleotide release have been proposed in which the P2X receptor, MRP, and connexins are believed to release nucleotides from purinergic cells (1) . The identification of VNUT revealed the presence of a regulated exocytosis pathway. Thus, by examining the distribution of VNUT, the source of the purinergic signal output can be identified. Thus VNUT is a new probe for purinergic signaling (43). Recent histochemical analyses show that VNUT is present in various tissues (35, 47, 59, 68, 105). Vessey and Fletcher found that VNUT and P2X7 receptors are located in the retina and contribute to purinergic signaling for modulation of post-photoreceptor response in both rod and cone pathways (105) . In the pancreas, VNUT is found in zymogen granules and has been suggested to participate in the regulation of ductal secretion (35). VNUT is expressed in esophageal keratinocytes and has been suggested to be involved in TRPV4-dependent ATP release induced by heat and chemical stimuli (68) . In addition, involvement of VNUT in taste sensing has been proposed (47). The authors found that VNUT is localized in type II taste cells that mediate sweet, bitter, and umami taste sensing (47). Taken together, identification of VNUT revealed the presence of purinergic signaling in various tissues and the diverse functions of the purinergic system (43).
Like VNUT, the vesicular aspartate transporter was identified by employing the same technique (69) . Aspartate is costored with glutamate in the subset of synaptic vesicles in neurons; however, the mechanism of vesicular accumulation of aspartate is not understood (34). VGLUTs do not recognize aspartate as a substrate even though structurally similar to glutamate. Although it is reasonable to hypothesize that one of SLC17 family transporters is responsible for aspartate transport, neither NPT nor VNUT recognizes aspartate as a substrate (69) .
Sialin or SLC17A5 protein has been identified as a lysosomal sialic acid transporter (75, 104) . Mutation of the sialin gene causes sialic acid metabolism malfunction and results in Salla disease (104) . Sialin is highly expressed in brain and is also found in nonlysosomal components (8). This suggests that sialin has other unknown functions in addition to sialic acid transport in lysosomes. When purified sialin was reconstituted in liposomes, it showed membrane potential-driven aspartate transport (69) . Sialin showed Cl Ϫ dependence and inhibitor profiles similar to that of VGLUT but recognizes both aspartate and glutamate as substrates. These results and the localization of sialin on synaptic vesicles indicate that sialin is the vesicular excitatory amino acid transporter (VEAT) (69) . Sialin is a unique protein that changes its function depending on location. In lysosomes, it plays an essential role in sialic acid metabolism as a H ϩ /sialic acid cotransporter, and when it is in synaptic vesicles, sialin functions as a membrane potential-driven aspartate and glutamate transporter (69, 75) . Thus it works as a double function transporter.
Cl

؊ as a Regulator of Signal Transmission
It is well known that cytosolic levels of Cl Glutamate transport by purified VGLUT is stimulated by Cl Ϫ in a cooperative manner. Acetoacetate, a ketone body (keto acid), inhibits VGLUT activity by reducing its affinity to Cl Ϫ . Glutamate accumulation in synaptic vesicles is regulated by a balance between Cl Ϫ stimulation and keto-acid inhibition. This, in turn, affects higher-ordered glutamatergic signaling. FIGURE 3 ). Among these substances, acetoacetate is well known as a ketone body. It is one of the metabolic intermediates of fatty acids, and its concentration is increased during starvation and consumption of a ketogenic diet. During starvation, the acetoacetate concentration is increased and inhibits VGLUT activity by competition with Cl Ϫ . Acetoacetate also reduces the quantum release of glutamate and causes artificial seizures in mice (54).
These results indicate that glutamatergic signaling is affected by the metabolic state of the organism. The inhibition of VGLUT by pyruvate, ␣-keto-␤-methyl-valeric acid, and phenylpyruvate indicates a correlation of glutamatergic signaling with amino acid and energy metabolism. Since the latter two keto acids are the product of phenylketonuria and maple syrup urine diseases, glutamatergic chemical transmission may be perturbed in patients suffering from these metabolic diseases. Regulation of transport activity by Cl Ϫ is also observed in VNUT, VEAT, and other SLC17 transporters. This suggests purinergic signaling may also be affected by the Cl Ϫ /keto acid system. Considering the involvement of cytosolic Cl Ϫ in vesicular electrochemical gradient of H ϩ and GABA accumulation, Cl Ϫ is a fundamental signal transmission regulator.
Conclusions and Insights
In 
